Targets › INHBA
3 programs from 3 companies in 16 trials: 7 Phase 2, 5 Phase 4, 3 Phase 3, 1 Phase 1; Cardiovascular, Oncology, Metabolic and endocrine; next expected readout Jul 2027.
Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition..; FUNCTION: Activin A is a homodimer of INHBA that plays a role in several…. (UniProt, P08476)
Open in Phaseline: the race on INHBA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Merck & Co. (MSD) | Sotatercept (MK-7962) Inhibin beta A chain inhibitor | INHBA | Phase 4 | Pulmonary Arterial Hypertension; Hypertension, Pulmonary; Pulmonary Arterial Hypertension PAH; Eisenmenger Syndrome … | Apr 2028 |
| Regeneron Pharmaceuticals | Garetosmab Inhibin beta A chain inhibitor | INHBA | Phase 3 | Fibrodysplasia Ossificans Progressiva; Obesity | Feb 2029 |
| Massachusetts General Hospital | Activin ligand-trap biological therapy Activin ligand trap (sequesters activin A and activin B) | INHBA, INHBB | Phase 2 | Heart Failure With Preserved Ejection Fraction | Jul 2027 |
Pulmonary Arterial Hypertension (6) Hypertension, Pulmonary (1) Pulmonary Arterial Hypertension PAH (1) Eisenmenger Syndrome (1) Pulmonary Artery Hypertension (1) Pulmonary Arterial Hypertension (PAH) (1) Pulmonary Hypertension (1) Multiple Myeloma (1) Heart Failure With Preserved Ejection Fraction (1) Fibrodysplasia Ossificans Progressiva (1) Obesity (1)
antibody (1), small molecule (1), mixed (1)
Merck & Co. (MSD) (1) Massachusetts General Hospital (1) Regeneron Pharmaceuticals (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.